CLIAC Seeks Role In FDA's Revision Of Lab Test Waiver Policy
This article was originally published in The Gray Sheet
Executive Summary
The Clinical Laboratory Improvement Advisory Committee (CLIAC) requests that FDA postpone guidance or rulemaking on CLIA waiver applications until it makes recommendations on the issue at a February or March 2001 meeting.
You may also be interested in...
GHTF Pilot Update: Japan Joins In, US/Canada To Coordinate Parallel Reviews
FDA's existing joint review program with Canada could be a vehicle for the agency to conduct parallel reviews of cardiovascular devices using the Global Harmonization Task Force's common premarket submission format
GHTF Pilot Update: Japan Joins In, US/Canada To Coordinate Parallel Reviews
FDA's existing joint review program with Canada could be a vehicle for the agency to conduct parallel reviews of cardiovascular devices using the Global Harmonization Task Force's common premarket submission format
HHS Sign-Off Critical To CLIA Waiver Proposal: FDA Criteria At Odds With CMS'
Manufacturers seeking CLIA waivers for in vitro diagnostics should wait until FDA's interim guidance is finalized before using the alternative approach it outlines, according to CDRH.